3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Burkitt Lymphoma
1
Interventions
Rituximab
32
Cyclophosphamide
28
Lenalidomide
19
Prednisone
16
Doxorubicin
16
Vincristine
14
Etoposide
11
CT-P10
11
Gemcitabine
9
polatuzumab vedotin
8
Oxaliplatin
7
ibrutinib
6
glofitamab
6
fludarabine
6
acalabrutinib
6
Magnetic Resonance Spectroscopy
6
Ifosfamide
6
Carboplatin
6
tafasitamab
5
prednylidene
5
pembrolizumab
5
obinutuzumab
5
deltacortene
5
Specimen Handling
5
R-CHOP protocol
5
Nivolumab
5
Biopsy
5
venetoclax
4
fludarabine phosphate
4
selinexor
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Lymphoma, Large B-Cell, Diffuse
×
Maintenance
×
Clear all
NCT04542824
2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled